# US 2026/0226116 A1 · Treatment of fragile x syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0226116 A1
- Document ID: US20260226116A1
- Status: Published application
- Kind: A1
- Application number: 19/146,332
- Filed: 2024-01-11
- Published: 2026-08-06
- Earliest claimed: 2023-01-11
- Assignees: UTI Limited Partnership
- Applicants: Uti Limited Partnership
- Inventors: Raymond W. TURNER; Xiaogin ZHAN; Hadhimulya ASMARA
- Web page: https://patentgrep.com/patent/US20260226116A1

## CPC

- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07K 14/4702: {Regulators; Modulating activity}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K 2319/21: containing a His-tag
- C07K 2319/41: containing a Myc-tag
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12Y 207/10001: Receptor protein-tyrosine kinase (2.7.10.1)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates generally to the treatment of Fragile X Syndrome.

## Claims

### Claim 1

A recombinant fusion polypeptide, comprising: a FMRP(444-632) polypeptide and a cell penetrating polypeptide, or fragment or variant thereof.

### Claim 2 (depends on 1)

The recombinant fusion polypeptide of claim 1, where said cell penetrating polypeptide comprises a tat polypeptide.

### Claim 3 (depends on 1, 2)

The recombinant fusion polypeptide of claim 1 or 2, further comprising a linker positioned between said cell penetrating polypeptide and said FMRP(444-632) polypeptide.

### Claim 4 (depends on 3)

The recombinant fusion polypeptide of claim 3, wherein the linker is GSGGG (SEQ ID NO:11).

### Claim 5 (depends on 2, 3, 4)

The recombinant fusion polypeptide of any one of claims 2 to 4, where said tat polypeptide comprises YGRKKRRQRRR (SEQ ID NO: 4).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The recombinant fusion polypeptide of any one of claims 1 to 5, further comprising a HIS polypeptide.

### Claim 7 (depends on 6)

The recombinant fusion polypeptide of claim 6, wherein said HIS polypeptide comprises HHHHHH (SEQ ID NO:12) or MGGSHHHHHHGMAS (SEQ ID NO: 5).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The recombinant fusion polypeptide of any one of claims 1 to 7, further comprising an immunogenic tag.

### Claim 9 (depends on 8)

The recombinant fusion polypeptide of claim 8, wherein the immunogenic tag is a c-myc tag.

### Claim 10 (depends on 9)

The recombinant fusion polypeptide of claim 9, wherein the c-myc tag is EQKLISEEDL (SED ID NO: 6).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The recombinant fusion polypeptide of any one of claims 1 to 10, wherein the FMRP(444-632) polypeptide is
(SEQ ID NO: 7)
MGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNA
SETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGND
DHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRN
QKKEKPDSVDGQQPLVNGVP.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The recombinant fusion polypeptide of any one of claims 1 to 11, wherein the sequence is
(SEQ ID NO: 3)
MGGSHHHHHHGMASEQKLISEEDLMGASSRPPPNRTDKEKSYVTDDGQGMGRGSRP
YRNRGHGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGR
RRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQNTSSEGSR
LRTGKDRNQKKEKPDSVDGQQPLVNGVPGSGGGYGRKKRRQRRR.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The recombinant fusion polypeptide of any one of claims 1 to 12, wherein said fusion polypeptide comprises a variant fusion polypeptide sequence that is at least 80% identical to said fusion polypeptide.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A polynucleotide molecule comprising or consisting of a sequence that encodes a recombinant fusion polypeptide according to any one of claims 1 to 13.

### Claim 15 (depends on 14)

A vector comprising the polynucleotide molecule of claim 14.

### Claim 16 (depends on 14)

A cell comprising the polynucleotide molecule of claim 14.

### Claim 17 (depends on 15)

A cell comprising the vector of claim 15.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A pharmaceutical composition comprising a recombinant fusion polypeptide of any one of claims 1-13, a polynucleotide molecule of claim 14, or a vector of claim 15, and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18)

A method of treatment of a subject having or suspected of having Fragile X Syndrome, comprising: administering a recombinant fusion polypeptide of any one of claims 1 to 13, a polynucleotide molecule of claim 14, a vector of claim 15, or a pharmaceutical composition of claim 18, to said subject.

### Claim 20 (depends on 19)

The method of claim 19, further comprising administration of minocycline, metformin, and/or blockers of extracellular signal-regulated kinase (ERK).

### Claim 21 (depends on 19, 20)

The method of claim 19 or 20, wherein said subject is a human.

### Claim 22

A recombinant fusion polypeptide, comprising: a FMRP(399-570) polypeptide and a cell penetrating polypeptide, or fragment or variant thereof.

### Claim 23 (depends on 22)

The recombinant fusion polypeptide of claim 22, where said cell penetrating polypeptide comprises a tat polypeptide.

### Claim 24 (depends on 22, 23)

The recombinant fusion polypeptide of claim 22 or 23, further comprising a linker positioned between said cell penetrating polypeptide and said FMRP(399-570) polypeptide.

### Claim 25 (depends on 24)

The recombinant fusion polypeptide of claim 24, wherein the linker is GSGGG (SEQ ID NO:11).

### Claim 26 (depends on 23, 24, 25)

The recombinant fusion polypeptide of any one of claims 23 to 25, where said tat polypeptide comprises YGRKKRRQRRR (SEQ ID NO: 4).

### Claim 27 (depends on 22, 23, 24, 25, 26)

The recombinant fusion polypeptide of any one of claims 22 to 26, further comprising a HIS polypeptide.

### Claim 28 (depends on 27)

The recombinant fusion polypeptide of claim 27, wherein said HIS polypeptide comprises HHHHHH (SEQ ID NO: 12) or MGGSHHHHHHGMAS (SEQ ID NO: 5).

### Claim 29 (depends on 22, 23, 24, 25, 26, 27, 28)

The recombinant fusion polypeptide of any one of claims 22 to 28, further comprising an immunogenic tag.

### Claim 30 (depends on 29)

The recombinant fusion polypeptide of claim 29, wherein the immunogenic tag is a c-myc tag.

### Claim 31 (depends on 30)

The recombinant fusion polypeptide of claim 30, wherein the c-myc tag is EQKLISEEDL (SEQ ID NO: 6).

### Claim 32 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The recombinant fusion polypeptide of any one of claims 22 to 31, wherein the FMRP(399-570) polypeptide is
(SEQ ID NO: 8)
MGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNA
SETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGND
DHSRTDNRPRNPREAKGRTTDGSLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQQPLV
NGVP.

### Claim 33 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The recombinant fusion polypeptide of any one of claims 22 to 32, wherein the sequence is
(SEQ ID NO: 3)
MGGSHHHHHHGMASEQKLISEEDLMGASSRPPPNRTDKEKSYVTDDGQGMGRGSRP
YRNRGHGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGR
RRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQNTSSEGSR
LRTGKDRNQKKEKPDSVDGQQPLVNGVPGSGGGYGRKKRRQRRR.

### Claim 34 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The recombinant fusion polypeptide of any one of claims 22 to 33, wherein said fusion polypeptide comprises a variant fusion polypeptide sequence that is at least 80% identical to said fusion polypeptide.

### Claim 35 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A polynucleotide molecule comprising or consisting of a sequence that encodes a recombinant fusion polypeptide according to any one of claims 22 to 34.

### Claim 36 (depends on 35)

A vector comprising the polynucleotide molecule of claim 35.

### Claim 37 (depends on 35)

A cell comprising the polynucleotide molecule of claim 35.

### Claim 38 (depends on 36)

A cell comprising the vector of claim 36.

### Claim 39 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

A pharmaceutical composition comprising a recombinant fusion polypeptide of any one of claims 22-34, a polynucleotide molecule of claim 35, or a vector of claim 36, and a pharmaceutically acceptable carrier.

### Claim 40 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 39)

A method of treatment of a subject having or suspected of having Fragile X Syndrome, comprising: administering a recombinant fusion polypeptide of any one of claims 22 to 34, a polynucleotide molecule of claim 35, a vector of claim 36, or a pharmaceutical composition of claim 39, to said subject.

### Claim 41 (depends on 40)

The method of claim 40, further comprising administration of minocycline, metformin, and/or blockers of extracellular signal-regulated kinase (ERK).

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, wherein said subject is a human.

### Claim 43

A recombinant fusion polypeptide, comprising: a FMRP(205-399) polypeptide and a cell penetrating polypeptide, or fragment or variant thereof.

### Claim 44 (depends on 43)

The recombinant fusion polypeptide of claim 43, where said cell penetrating polypeptide comprises a tat polypeptide.

### Claim 45 (depends on 43, 44)

The recombinant fusion polypeptide of claim 43 or 44, further comprising a linker positioned between said cell penetrating polypeptide and said FMRP(205-399) polypeptide.

### Claim 46 (depends on 45)

The recombinant fusion polypeptide of claim 45, wherein the linker is GSGGG (SEQ ID NO:11).

### Claim 47 (depends on 44, 45, 46)

The recombinant fusion polypeptide of any one of claims 44 to 46, where said tat polypeptide comprises YGRKKRRQRRR (SEQ ID NO: 4).

### Claim 48 (depends on 43, 44, 45, 46, 47)

The recombinant fusion polypeptide of any one of claims 43 to 47, further comprising a HIS polypeptide.

### Claim 49 (depends on 48)

The recombinant fusion polypeptide of claim 48, wherein said HIS polypeptide comprises HHHHHH (SEQ ID NO: 12) or MGGSHHHHHHGMAS (SEQ ID NO: 5).

### Claim 50 (depends on 43, 44, 45, 46, 47, 48, 49)

The recombinant fusion polypeptide of any one of claims 43 to 49, further comprising an immunogenic tag.

### Claim 51 (depends on 50)

The recombinant fusion polypeptide of claim 50, wherein the immunogenic tag is a c-myc tag.

### Claim 52 (depends on 51)

The recombinant fusion polypeptide of claim 51, wherein the c-myc tag is EQKLISEEDL (SEQ ID NO: 6).

### Claim 53 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The recombinant fusion polypeptide of any one of claims 43 to 52, wherein the FMRP(205-399) polypeptide is
(SEQ ID NOa: 1)
MSKQLESSRQLASRFHEQFIVREDLMGLAIGTHGANIQQARKVPGVTAIDLDEDTCTFHI
YGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKNGKLIQEIVDKSGVVRVRIEAENEK
NVPQEEVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYHLNYLKEVD
QLRLERLQIDEQLRQI.

### Claim 54 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The recombinant fusion polypeptide of any one of claims 43 to 53, wherein the sequence is
SEQ ID NO: 9)
MGGSHHHHHHGMASEQKLISEEDLMSKQLESSRQLASRFHEQFIVREDLMGLAIGTHG
ANIQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGK
NGKLIQEIVDKSGWVRVRIEAENEKNVPQEEVLVASSVVAGESQKPELKAWQGMVPFVF
VGTKDSIANATVLLDYHLNYLKEVDQLRLERLQIDEQLRQIGSGGGYGRKKRRQRRR.

### Claim 55 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The recombinant fusion polypeptide of any one of claims 43 to 54, wherein said fusion polypeptide comprises a variant fusion polypeptide sequence that is at least 80% identical to said fusion polypeptide, or fragments or variants thereof.

### Claim 56 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A polynucleotide molecule comprising or consisting of a sequence that encodes a recombinant fusion polypeptide according to any one of claims 43 to 55.

### Claim 57 (depends on 56)

A vector comprising the polynucleotide molecule of claim 56.

### Claim 58 (depends on 56)

A cell comprising the polynucleotide molecule of claim 56.

### Claim 59 (depends on 57)

A cell comprising the vector of claim 57.

### Claim 60 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A pharmaceutical composition comprising a recombinant fusion polypeptide of any one of claims 43-55, a polynucleotide molecule of claim 56, or a vector of claim 57, and a pharmaceutically acceptable carrier.

### Claim 61 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 60)

A method of treatment of a subject having or suspected of having Fragile X Syndrome, comprising: administering a recombinant fusion polypeptide of any one of claims 43 to 55, a polynucleotide molecule of claim 56, a vector of claim 57, or a pharmaceutical composition of claim 60, to said subject.

### Claim 62 (depends on 61)

The method of claim 61, further comprising administration of minocycline, metformin, and/or blockers of extracellular signal-regulated kinase (ERK).

### Claim 63 (depends on 61, 62)

The method of claim 61 or 62, wherein said subject is a human.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 39, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 60)

A method of treatment of a subject having or suspected of having Fragile X Syndrome, comprising:
administering a recombinant fusion polypeptide of any one of claims 1 to 13, a polynucleotide molecule of claim 14, a vector of claim 15, or a pharmaceutical composition of claim 18, to said subject and/or
administering a recombinant fusion polypeptide of any one of claims 22 to 34, a polynucleotide molecule of claim 35, a vector of claim 36, or a pharmaceutical composition of claim 39, to said subject, and/or
administering a recombinant fusion polypeptide of any one of claims 43 to 55, a polynucleotide molecule of claim 56, a vector of claim 57, or a pharmaceutical composition of claim 60, to said subject.

### Claim 65 (depends on 64)

The method of claim 64, further comprising administration of minocycline, metformin, and/or blockers of extracellular signal-regulated kinase (ERK).

### Claim 66 (depends on 64, 65)

The method of claim 64 or 65, wherein said subject is a human.
